NCT00005083

Brief Summary

RATIONALE: New imaging procedures, such as functional magnetic resonance imaging and 1H-nuclear magnetic resonance spectroscopic imaging, may improve the ability to detect the extent of cancer in the brain. PURPOSE: Phase II trial to study the effectiveness of functional magnetic resonance imaging and 1H-nuclear magnetic resonance spectroscopic imaging in treating patients who have newly diagnosed brain tumors.

Trial Health

10
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Status
withdrawn

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 1, 1998

Completed
2.1 years until next milestone

First Submitted

Initial submission to the registry

April 6, 2000

Completed
3.7 years until next milestone

First Posted

Study publicly available on registry

December 16, 2003

Completed
Last Updated

October 4, 2012

Status Verified

October 1, 2012

First QC Date

April 6, 2000

Last Update Submit

October 2, 2012

Conditions

Brain and Central Nervous System Tumors

Keywords

adult glioblastomaadult anaplastic astrocytomaadult myxopapillary ependymomaadult anaplastic ependymomaadult anaplastic oligodendrogliomaadult mixed gliomaadult pilocytic astrocytomaadult subependymomaadult ependymoblastomaadult oligodendrogliomaadult giant cell glioblastomaadult gliosarcoma

Interventions

conventional surgeryPROCEDURE
magnetic resonance imagingPROCEDURE
magnetic resonance spectroscopic imagingPROCEDURE

Eligibility Criteria

Age18 Years - 55 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64)
DISEASE CHARACTERISTICS: Newly diagnosed brain tumor Neuroradiological and clinical evidence of probable glioma Lesion in close proximity to language and motor areas No prior resection PATIENT CHARACTERISTICS: Age: 18 to 55 Performance status: Not specified Life expectancy: Not specified Hematopoietic: Not specified Hepatic: Not specified Renal: Not specified Other: No other medical or psychiatric disorder No contraindications to MRI scanning (e.g., metal implants, dental prostheses other than fillings, contrast allergies) PRIOR CONCURRENT THERAPY: See Disease Characteristics

Contact the study team to discuss eligibility requirements. They can help determine if this study is right for you.

Sponsors & Collaborators

MeSH Terms

Conditions

Central Nervous System NeoplasmsGlioblastomaAstrocytomaEpendymomaOligodendrogliomaGliomaGlioma, SubependymalNeuroectodermal Tumors, PrimitiveGliosarcoma

Interventions

Magnetic Resonance Spectroscopy

Condition Hierarchy (Ancestors)

Nervous System NeoplasmsNeoplasms by SiteNeoplasmsNervous System DiseasesNeoplasms, NeuroepithelialNeuroectodermal TumorsNeoplasms, Germ Cell and EmbryonalNeoplasms by Histologic TypeNeoplasms, Glandular and EpithelialNeoplasms, Nerve Tissue

Intervention Hierarchy (Ancestors)

Spectrum AnalysisChemistry Techniques, AnalyticalInvestigative Techniques

Study Officials

  • Jeffry Alger, PhD

    Jonsson Comprehensive Cancer Center

    STUDY CHAIR
0

Study Design

Study Type
interventional
Phase
phase 2
Purpose
DIAGNOSTIC
Sponsor Type
OTHER

Study Record Dates

First Submitted

April 6, 2000

First Posted

December 16, 2003

Study Start

March 1, 1998

Last Updated

October 4, 2012

Record last verified: 2012-10